NK cells can prevent the occurrence and development of tumor cells. However, due to cancer immunosuppression, the patient's immune system is suppressed and cannot prevent the development of the disease.
The production of clinical-grade activated and expanded NK cells is expected to delay the deterioration of the disease; inhibit tumor growth, prolong the survival rate of patients, and improve the quality of life.